adverum.com (ADVM) Year-over-year earnings per share growth for the last twelve months

Corporate emblem and logo of Adverum Biotechnologies (ADVM)

Will patents and strict FDA control protect Adverum Biotechnologies (ADVM) from competitors? Adverum Biotechnologies is developing the unique Ixo-vec vector, which replaces frequent injections for macular dystrophy with a single procedure. However, cash flows remain unstable and dependent on grants. The quarter-over-quarter EPS trend confirms this volatility, with the current level standing at -55.70.

adverum.com (ADVM) - Quarterly EPS earnings growth from 07/04/2022 to 12/20/2025

Financial and market metric breakdowns for adverum.com (ADVM)

- share price and expert price forecast:
Comprehensive company analysis:Adverum Biotechnologies
Finished products of Adverum Biotechnologies

Adverum Biotechnologies (ADVM) vulnerability to supply chain disruptions and patent disputes amid geopolitical pressure makes monitoring financial stability critical. The earnings per share dynamics, reflected through the growth rate of quarterly EPS, measures the rate of change in net income adjusted for probability distribution, allowing investors to identify hidden growth potential or the risk of a price collapse during periods of low volatility.

Who Adverum Biotechnologies competes with

Alcon Corp (ALC) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Bausch Health (BLCO)|Year-over-year earnings per share growth for the last twelve months glaukos.com|Apellis Pharmaceuticals (APLS) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth BLTE|OCUL - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth HROW (Harrow Inc)|Year-over-year net earnings per share change for the last twelve months Viridian Corp (VRDN)|LENZ - Year-over-year earnings per share growth for the last twelve months|Oculis - Year-over-year earnings per share growth rate for the last twelve months|EyePoint Pharmaceuticals (EYPT) - Year-over-year earnings per share growth for the last twelve months|Kodiak Sciences Inc (KOD) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months ALDX|KALA: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth IRD|OKYO: Year-over-year net earnings per share trend for the last twelve months|Year-over-year earnings per share growth for the last twelve months outlooktherapeutics.com OTLK|Year-over-year net earnings per share change for the last twelve months Clearside Biomedical, Inc. (CLSD)|NBY - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months KPRX (kiorapharma.com)|Alimera Sciences (ALIM) - Year-over-year earnings per share growth for the last twelve months|Eyenovia Inc. - Year-over-year earnings per one share growth for the last 12 months|GHSI (Guardion Health Sciences) - Quarterly EPS earnings growth|Ocuphire Pharma - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OPT (Opthea)